In January 2025, nearly 30 medical device companies worldwide completed a new round of financing, with a total amount exceeding 6 billion yuan.

Source of the image: Pharma Data Enterprise Edition - Investment Landscape Database

Data as of January 26, 2024

Among them, multipleChinese companies completed billions of yuan in financing in January。

• Haofeng Medical

In early January, Haofeng Medical announced the completion of a nearly RMB 100 million Pre-B round of financing. This round was led by Zhuhai High-Tech Investment, with existing shareholder Qianji Capital continuing to increase its investment. The funds raised will be mainly used for the company's capacity expansion, business development, and global layout, accelerating product and service diversification, and strengthening its leading position in the interventional medical device field.

Haofeng Medical is a leading CDMO (Contract Development and Manufacturing Organization) platform company in China for Class III interventional medical devices, dedicated to serving global interventional medical device manufacturers. Its main product lines include Class III high-value medical devices (covering multiple fields such as cardiovascular, peripheral vascular, and intracranial vascular), as well as active medical devices. Some of its products, which partially replace imported technologies, are globally leading.

• BOIN Hearing

In early January, BOIN Hearing Technology announced the completion of a new round of strategic financing, with an amount close to 100 million RMB. This round of financing was jointly led by Guangzhou Industrial Investment and Capital Gold, with Haoyue Capital serving as the exclusive financial advisor for this transaction.

BOIN Hearing Technology(SH) Co.,LTD. was founded in Minhang District, Shanghai in 2019. It was awarded the title of "National High-tech Enterprise" twice in 2021 and 2024, and received the title of "Innovative Small and Medium-sized Enterprise" in 2023. It is a leading enterprise specializing in self-developed medical-grade hearing aids. Currently, BOIN Hearing has grown into one of the few domestic hearing aid brands in China that possess both independent research and development capabilities and high-quality services, establishing its own unique ecosystem and first-mover advantage.

• Shenzhen Kunwei Technology Co., Ltd

In early January, Shenzhen Kunwei Technology Co., Ltd. announced the completion of an A+ round of financing exceeding RMB 100 million. This round of financing was led by Tencent Investment, with co-investments from Hengqin Venture Capital under Gree Group, Qianhai Ark, Shenzhen Guarantee Venture Capital,卓源亚洲, and Sherpa Healthcare Partners. Berrington Capital served as the exclusive financial advisor for this round of financing.

Shenzhen Kunwei Technology Co., Ltd. was founded in October 2019 in Shenzhen, and has always been committed to the innovation of super-resolution imaging technology. Within just five years, Kunwei Technology not only transformed the conceptual design of disruptive technology into reality but also achieved a leap from prototype development to product launch. Relying on its proprietary kOS ultrasound operation platform, Kunwei Technology expanded its range of desktop and portable super-resolution ultrasound products, achieving efficient connection and advancement from theoretical exploration to commercial practice. With existing ultrasound imaging technology being fully exploited and approaching performance limits, Kunwei Technology adheres to first principles to redefine ultrasound imaging technology, overcoming the final barrier in ultrasound application.

• Fourier Intelligence

On January 7, Fourier Intelligence announced the completion of a new round of financing, with the total amount of Series E financing reaching nearly 800 million yuan. This round of financing was jointly participated by Guoxin Investment, Pudong Venture Capital, Zhangjiang Science & Technology Investment, Zhangjiang Keyunkun Fund, Prosperity7, and Junshan Capital, injecting strong momentum into Fourier Intelligence's continuous innovation in the robotics field.

Shanghai Fourier Intelligence Co., Ltd. is a leading general robotics company in the industry, with a product pipeline covering core humanoid robot businesses and intelligent rehabilitation solutions. Since its establishment in 2015, Fourier has been committed to developing robots that combine cutting-edge technology with commercial value. Currently, its products are widely used in real-world scenarios such as medical rehabilitation and academic research, providing support and services to over 2,000 institutions and hospitals in more than 40 countries and regions worldwide.

• Conorth

On January 13, Conorth announced the completion of a C-round financing exceeding 500 million RMB. This round of financing was led by EQT, a large European private equity investment group, with participation from Qiming Venture Partners, Alpha JWC Ventures, InnoVen Capital, eGarden Ventures, Pinehill Capital, K2VC, and Meituan Longzhu, among other professional investment institutions from home and abroad. UBS Group served as the financial advisor for this round of financing. The funds raised will drive the company to accelerate its commercialization process, develop new surgical robot products, conduct clinical trials, and promote global business development and cooperation.

Connexstent, after five years of rapid and high-quality development, has established three major R&D centers worldwide. It fully masters core technologies such as mechanical architecture, electrical architecture, software architecture, complex algorithms, and visual imaging, independently building a foundational technology platform for surgical robots. Additionally, it operates a mass-production facility exceeding 10,000 square meters in the Greater Bay Area, successfully achieving "independent research and development and independent manufacturing" of surgical robots. 2024 marks the commercialization debut year for Connexstent, with its self-developed Sentire® laparoscopic surgical robot officially receiving NMPA approval for market launch on September 29, 2024.

• Nuo Yi Mai Er

On January 14, Numenova announced the completion of a nearly 300 million yuan C-round financing. This round was led by the New Materials Fund of Shenzhen Capital Group's Manufacturing Transformation and Upgrading Investment, with participation from some existing shareholders and management. WinX Capital served as the exclusive financial advisor for this round. The funds will mainly be used for the commercial promotion, clinical trials, and implementation of Numenova's international strategy for its multiple innovative medical device products.

Nuo Yimai'er, established in March 2017, was co-founded by a team of Chinese and German scientists led by a recipient of China's National Key Talent Project. It is an innovative enterprise specializing in the research, development, production, and commercialization of regenerative implantable medical devices. Nuo Yimai'er adheres to the goal of independent innovation, striving for domestic firsts and international leadership. The company has mastered core technologies ranging from advanced raw material design, proprietary equipment development, key process preparation, to clinical application of its products. It has achieved industrialized applications of key technical routes in the field of tissue engineering materials, such as electrospinning, 3D printing, and chemical synthesis. Its diverse product portfolio includes membranes, bone materials, gels, agents, microspheres, and more, extending across multiple clinical departments including dentistry, ophthalmology, reproductive medicine, sports medicine, otolaryngology, and surgery. Nuo Yimai'er has become one of the most comprehensive solution providers in China’s regenerative medical materials sector, boasting the widest product coverage and the most advanced technology.

• Suzhou Meichuang

On January 15, Haofeng announced the completion of an over RMB 100 million Series A+ round of financing. This round was co-led by Sequoia China and EF Capital, with participation from Industrial Securities Capital and Pinecrest Capital. WinX Capital served as the exclusive financial advisor. The funds will be used for the construction of medical implant-grade ePTFE production lines, innovative product research and development, and the commercial promotion of certified products. This is expected to help Haofeng successfully address the bottleneck issue of core raw material ePTFE in the medical device industry and become a market leader in this field.

Suzhou Meichuang is a leading platform company specializing in the research, production, manufacturing, and commercialization of high-end implantable and interventional medical devices based on core technology in medical-grade ePTFE materials. Its implantable ePTFE materials and related device products are widely used in high-growth fields such as vascular intervention, oncology intervention, and surgical procedures, including vascular stent grafts, non-vascular stent grafts, artificial blood vessels, various patches, surgical sutures, cosmetic fillers, intracranial dura mater/spinal membranes, oral bone membranes, endoscopic biopsy channels, and expandable vascular sheaths.

• Xianwei Vision

On January 16, Xianwei Vision announced the completion of an over 100-million-yuan Series A financing round, led by Lilly Asia Ventures and followed by Cowin Venture Capital. The funds raised will be used to promote the clinical trials and registration submission of the "Femtosecond Laser Corneal Refractive Surgery Device," accelerating the product's market entry and commercialization process.

Xianwei Vision was founded in 2022, with its core technology originating from the research achievements of Wuhan National Laboratory for Optoelectronics at Huazhong University of Science and Technology. It was co-founded by Professor Shaoqun Zeng, a life optoelectronics scientist from the center, serial entrepreneur Cao Feng, and seasoned ophthalmology professionals. Focusing on the development of high-end ophthalmic surgical equipment, Xianwei Vision has comprehensively laid out femtosecond refractive correction surgery devices and excimer laser surgery equipment, striving to become a game-changer in China's femtosecond laser corneal refractive surgery equipment industry.

• Xin Zeyuan

On January 20, Xinzeyuan announced the successful completion of a nearly 100-million-yuan B+ round of financing. This round was jointly invested by Shunbai Fund and Sanmei Investment, with continued investment from existing shareholder Qiming Venture Capital. Dianshi Capital continued to serve as the exclusive financial advisor. It is reported that Xinzeyuan has completed two rounds of financing within half a year.

Xin Zeyuan was established in 2015, serving a wide range of medical brands with four major business modules: rigid endoscopes, flexible endoscopes, endoscopic surgical instruments, and minimally invasive surgical instruments. Xin Zeyuan operates two production bases located in Qingshan Lake and Changhua Industrial Park, with a total area exceeding ten thousand square meters. It is equipped with hundreds of high-end production devices, producing over 30,000 types of parts and more than 3,200 types of components.

• AOYI Technology

On January 21, Aoi Technology announced the completion of a nearly RMB 100 million Series B+ financing round. This round was led by Huafa Group, with participation from Guangda Huitong and He Ying Capital. Sheng氪Agent Capital served as the financial advisor to Aoi Technology in this transaction. The funds from this round will help Aoi Technology establish a high-standard production system, completing the last piece of their commercial blueprint.

OYMotion Technology was founded in 2015 in the Zhangjiang High-Tech Park in Shanghai. Focusing on the intersection of two core technologies—brain science and robotics—the company has successfully built a research and development platform that integrates neural interfaces, robotics, and artificial intelligence technologies. It has launched several products with both high technical barriers and cost-effectiveness, gaining widespread recognition in domestic and international markets. OYMotion is a leading high-tech enterprise in China with expertise in both brain-computer interface and robotics as its foundational technologies.